588-26-1

Upstream product

• 67-56-1 methanol 
• 349-82-6 (3-trifluoromethylphenoxy)acetic acid 
• 98-17-9 3-Trifluoromethylphenol 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 63212-89-5 (3-trifluoromethylphenoxy)acetaldehyde 
• 331-45-3 (3-trifluoromethyl-phenoxy)-acetic acid-(2-hydroxy-ethylamide) 
• 88462-65-1 (+/-)-4-[(3-trifluoromethyl)phenoxy]-1-butyne-3-ol 
• 349-82-6 (3-trifluoromethylphenoxy)acetic acid 
• 54094-19-8 dimethyl [3-(3-(trifluoromethyl)phenoxy)-2-oxopropyl]phosphonate 
• 54142-64-2 [1,1'-biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]-2H-cyclopenta[b]furan-5-yl ester 
• 114488-92-5 (3aR,4R,5R,6aS)-4-((S,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl biphenyl-4-carboxylate 
• 114488-91-4 [1,1'-biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]-2-oxo-2H-cyclopenta[b]furan-5-yl ester 
• 52073-64-0 2-(3-(trifluoromethyl)phenoxy)ethan-1-ol 
• 53872-60-9 (3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-one 
• 1204185-88-5 (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]-2H-cyclopenta[b]furan-2,5-diol 
• 340181-93-3 travoprost 
• 307557-56-8 3-trifluoromethylphenoxyacetic acid hydrazide 

Relevant academic research and scientific papers

Novel method for preparing Prostaglandin derivatives

Provided is a novel method for preparing prostaglandin derivatives. The method is suitable for mass production by effectively manufacturing prostaglandin derivatives with high yield. The method comprises the following steps: (S-1) adding a first reducing agent to a prostaglandin intermediate compound represented by chemical formula II and manufacturing a compound represented by chemical formula III; (S-2) manufacturing a compound represented by chemical formula IV from the compound represented by chemical formula III in the presence of a base; (S-3) adding a second reducing agent to the compound represented by chemical formula IV and manufacturing a compound represented by chemical formula V; and (S-4) performing Wittig reaction of the compound represented by chemical formula V and a compound represented by chemical formula VI, and manufacturing a compound represented by chemical formula I.COPYRIGHT KIPO 2017

Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2

Replacement of the dimethoxyphenyl moiety in the core skeleton of almorexant by appropriately substituted imidazoles afforded novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as potent dual orexin receptor antagonists. We describe in th

Synthesis of (±) travoprost and its analogs

A new synthetic approach for the antiglaucoma agent, travoprost (1) has been developed in four steps from key intermediate (2). Key transformations include Horner-Wadsworth-Emmons reaction and separation of diastereomers to obtain (±) travoprost (1) and its analogs.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

Use of 15-ketoprostaglandin E or F compounds for uterine contraction

A method of inducing uterine contraction which comprises administering, to a subject in need of such contraction, a uterine-contractionally effective amount of a prostanoic acid derivative selected from the group consisting of a) 15-ketoprostaglandin E compounds, and b) 15-ketoprostaglandin F compounds with the proviso that when the only one group, which is unsubstituted n-pentyl group, is attached to the carbon atom at the 15-position of the prostanoic acid nucleus and the bond between the carbon atoms at 5- and 6-positions is a double bond, then the bond between the carbon atoms at 13- and 14-positions is a single bond.